¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÅÀåÇÐȸ KSN-IAC(Integrated Academic Conference) 2022 ÅëÇÕÇмú´ëȸ(1ÀÏÂ÷) : 2022-09-24

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÅÀåÇÐȸ KSN-IAC(Integrated Academic Conference) 2022 ÅëÇÕÇмú´ëȸ(1ÀÏÂ÷) : 2022-09-24
±³À°ÀÏÀÚ : 2022-09-24
±³À°Àå¼Ò : ºÎ»ê, º¤½ºÄÚ  
±³À°ÁÖÁ¦ : KSN-IAC(Integrated Academic Conference) 2022 ÅëÇÕÇмú´ëȸ(1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ
¿¬¶ôó : 02-3486-8736  
À̸ÞÀÏ : ksn@ksn.or.kr      
±³À°Á¾·ù : ³»°úÀÇ»çÇÐ
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡   (ÀÏ¹Ý 4Á¡ / Çʼö 2Á¡)  
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 23 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í [»çÀüµî·Ï]¡á Àü¹®ÀÇ(±³¼ö,ºÀÁ÷ÀÇ,°³¿øÀÇ): 1ÀÏ-25,000/ÀüÀÏ50,000 ¡á ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç,¾à»ç,¿µ¾ç»ç,»çȸº¹Áö»ç,ÀÇ·á°ü·ÃÁ¾»çÀÚ: 1ÀÏ-10,000¿ø/ÀüÀÏ-20,000¿ø [ÇöÀåµî·Ï]¡á Àü¹®ÀÇ(±³¼ö,ºÀÁ÷ÀÇ,°³¿øÀÇ): 1ÀÏ-30,000/ÀüÀÏ60,000 ¡á ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç,¾à»ç,¿µ¾ç»ç,»çȸº¹Áö»ç,ÀÇ·á°ü·ÃÁ¾»çÀÚ: 1ÀÏ-15,000¿ø/ÀüÀÏ-30,000¿ø *¸¸65¼¼ÀÌ»óȸ¿ø, Çлý-¸éÁ¦      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-24 Room1 08:50~09:10 Incremental hemodialysis – Pros –  ÀÌÀå¿í(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 09-24 Room1 09:10~09:30 Incremental hemodialysis – Cons –  ¹Ú»ï¿¤(¼øõÇâÀÇ´ë) 
Åä·Ð 09-24 Room1 09:30~09:45 ÆгÎÅäÀÇ  ÀüÁø¼® Çö¿µÀ²(¼øõÇâÀÇ´ë ¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 09-24 Room1 09:45~10:05 SDM-ART: ¿¬±¸ °³¿ä, ÁøÇà»óȲ ¹× ±³À° »ç·Ê ¼Ò°³  ±è¼¼Áß(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09-24 Room1 10:05~10:25 SDM-ART: ÃßÀû »ç·Ê ¹× °³¼±»çÇ× ÅäÀÇ  ÀÓÁ¤ÈÆ(°æºÏÀÇ´ë) 
Åä·Ð 09-24 Room1 10:25~10:40 ÆгÎÅäÀÇ  Á¶ÀåÈñ °í°­Áö(°æºÏÀÇ´ë °í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-24 Room1 10:40~10:50 Break  () 
±³À°½Ã°£ 09-24 Room1 10:50~11:10 Reducing the risk of intradialytic hypotension by altering the composition of the dialysate  ±èÇö¿ì(Á¦ÁÖÀÇ´ë) 
±³À°½Ã°£ 09-24 Room1 11:10~11:30 Citrate- vs. acetate-based dialysate in hemodialysis: Clinical efficacy and safety  ±è¼Ò¹Ì(´Ü±¹ÀÇ´ë) 
Åä·Ð 09-24 Room1 11:30~11:45 ÆгÎÅäÀÇ  ½ÅÁ¾È£±è°æ¹Î¹æ±âÅÂ(À»ÁöÀÇ´ëÀ»ÁöÀÇ´ë´©¸®³»°ú) 
±³À°½Ã°£ 09-24 Room1 11:45~12:05 ÁßȯÀÚ ½ÅÀå ¿¬±¸È¸ ¹ßÀü¹æÇâ: Á¤Ã¥ ¹× ÁßȯÀÚ ÇÐȸ ¿¬°è ¹æ¾È  ÀÓ¼ºÀ±(ºÐ´ç¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 09-24 Room1 12:05~12:25 CRRT(continuous renal replacement therapy) ±â±â ¹× ÇÊÅÍ ±¹»êÈ­ ±â¼ú °³¹ß »ç¾÷  ±èµ¿±â(¼­¿ïÀÇ´ë) 
Åä·Ð 09-24 Room1 12:25~12:40 ÆгÎÅäÀÇ  ¹éÁøÇõÀÌÇϸ°Çѽ¼®(°è¸íÀÇ´ëºÎ»êÀÇ´ë¼­¿ï´ëº´¿ø) 
½Ä»ç 09-24 Room1 12:40~13:40 ½Ä»ç  () 
±³À°½Ã°£ 09-24 Room1 13:40~14:10 SGLT2(Sodium-glucose transport proteins)-inhibitor: endocrinologist perspective  ³ëÁ¤Çö(ÀÎÁ¦ÀÇ´ë ÀÏ»ê¹éº´¿ø) 
±³À°½Ã°£ 09-24 Room1 14:10~14:40 SGLT2(Sodium-glucose transport proteins)-inhibitor: nephrologist perspective  À¯ÅÂÇö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09-24 Room1 14:40~15:10 SGLT2(Sodium-glucose transport proteins)-inhigitor: cardiologist perspective  ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë) 
Åä·Ð 09-24 Room1 15:10~15:30 ÆгÎÅäÀÇ  Áø±Ôº¹±è¿øÀÌÀº¿µ(°è¸íÀÇ´ëÀüºÏÀÇ´ë¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09-24 Room1 15:30~15:40 Break  () 
±³À°½Ã°£ 09-24 Room1 15:40~16:10 ¼Ò¼È³×Æ®¿öÅ· ¹× ¹Ìµð¾î ÀÌ¿ë¿¡¼­ÀÇ ÀÇ·á À±¸®  ±èÁ¤¾Æ(µ¿¾ÆÀÇ´ë) 
±³À°½Ã°£ 09-24 Room1 16:10~16:40 ÀΰøÁö´É(AI) ½Ã´ëÀÇ ÀÇ·á À±¸® ¹®Á¦  ¾ç±¤¸ð(¼­¿ï»ï¼ºº´¿ø) 
±³À°½Ã°£ 09-24 Room1 16:40~17:10 ÀÇ·áºÐÀï °¨Á¤ »ç¾È¿¡ ´ëÇÑ ¹ý·üÀû Çؼ®  ±è¿¬Èñ(¹ý¹«¹ýÀÎ ÀǼº) 
±³À°½Ã°£ 09-24 Room1 17:10~17:40 »î°ú Á×À½ÀÇ °æ°è¿¡¼­ÀÇ »ý¸íÀ±¸®  ¹Ú»óÀº(¾È¾ç»ùº´¿ø) 
±³À°½Ã°£ 09-24 Room2 08:50~09:15 Chronic Kidney Disease  °­ÀºÁ¤(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 09-24 Room2 09:15~09:40 Chronic Kidney Disease-Mineral Bone Disorder  ±èÁöÀº(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-24 Room2 09:40~10:05 ¸¶À̵¥ÀÌÅÍ  Â÷ÁøÁÖ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-24 Room2 10:05~10:30 ¸¸¼ºÄáÆϺ´ µ¥ÀÌÅÍÀÇ Ç¥ÁØÈ­¿Í ¾ÈÀüÇÑ È°¿ë ¹× º¸»ó  ±èÁÖÇÑ(¼­¿ïÀÇ´ë) 
Åä·Ð 09-24 Room2 10:30~10:40 ÆгÎÅäÀÇ  ±è°æ¹ÎÀ±¼ºÇÑ(À»ÁöÀÇ´ëâ¿øÆÄƼ¸¶º´¿ø) 
±³À°½Ã°£ 09-24 Room2 10:40~10:50 Break  () 
±³À°½Ã°£ 09-24 Room2 10:50~11:15 Indications of Tolvaptan Treatment in ADPKD(Autosomal dominant polycystic kidney disease)  ±èÈ¿»ó(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09-24 Room2 11:15~11:40 Tips to Improve Compliance with Tolvpatan Treatment  À̹ÎÁ¤(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 09-24 Room2 11:40~12:05 Short-term Outcomes of Tolvaptan Treatment: Lessons Learned from ESSENTIAL Trial  ±è¿ëö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09-24 Room2 12:05~12:30 Hepatic Manifestation of ADPKD(Autosomal dominant polycystic kidney disease)  ±èÇö¼÷(ÇѸ²ÀÇ´ë) 
Åä·Ð 09-24 Room2 12:30~12:40 ÆгÎÅäÀÇ  ±è¿¹´Ï¿ÀÁöÀº(°¡Å縯ÀÇ´ëÇѸ²ÀǴ뵿ź¼º½Éº´¿ø) 
½Ä»ç 09-24 Room2 12:40~13:40 ½Ä»ç  () 
±³À°½Ã°£ 09-24 Room2 13:40~14:05 High & Low Uric acid levels in Kidney Disease  ±è±ÙÈ£(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 09-24 Room2 14:05~14:30 Uric acid and Cardiometabolic SD  ¹èÀºÁø(°æ»óÀÇ´ë) 
±³À°½Ã°£ 09-24 Room2 14:30~14:55 Best choice of ULT for Koreans  ¼ÛÁ¤¼ö(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 09-24 Room2 14:55~15:20 The Effectiveness and Safety of ULT for CKD(Chronic Kidney Disease) patients  ±èÁ°æ(ÇѸ²ÀÇ´ë) 
Åä·Ð 09-24 Room2 15:20~15:30 ÆгÎÅäÀÇ  Á¤°æȯÁ¤ÇõÁØÁ¤ÀçÇö(°æÈñÀÇ´ë°­³²º´¿ø°í·ÁÀÇ´ë¾È»êº´¿ø) 
±³À°½Ã°£ 09-24 Room1 15:30~15:40 Break  () 
±³À°½Ã°£ 09-24 Room2 15:40~16:05 Kidney transplantation in Alport syndrome ; donor & recipient issue   ½ÅÈ£½Ä(°í½ÅÀÇ´ë) 
±³À°½Ã°£ 09-24 Room2 16:05~16:30 Outcome and management of fabry disease after Kidney Transplantation  ÃÖÈ«»ó(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 09-24 Room2 16:30~16:55 Consideration before kidney transplant in ADPKD(autosomal dominant polycystic kidney disease)  Á¤º´ÇÏ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-24 Room2 16:55~17:20 Characteristics and management of aHUS(Atypical haemolytic-uraemic syndrome)  ±è¸í±Ô(°í·ÁÀÇ´ë) 
Åä·Ð 09-24 Room2 17:20~17:30 ÆгÎÅäÀÇ  ¹ÎÁö¿ø¹Ú¿äÇÑȲ¼±´ö(°¡Å縯ÀÇ´ë°Ç¾çÀÇ´ëÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 09-24 Room3 08:50~09:15 Fabry disease overview-genetics and disease manifestation  ±èÀ¯¹Ì(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 09-24 Room3 09:15~09:40 Renal manifestations & monitoring by nephrology  ¹ÚºÀ¼ö(ÀÎÁ¦ÀÇ´ë ÇØ¿î´ë¹éº´¿ø) 
±³À°½Ã°£ 09-24 Room3 09:40~10:05 cardiac manifestations & monitoring by cardiology  ±èÁöÈñ(°¡Å縯´ë ¼ººó¼¾Æ®º´¿ø) 
±³À°½Ã°£ 09-24 Room3 10:05~10:30 Neurologic manifestations of Fabry disease  ½ÅÁøÈï(ºÎ»êÀÇ´ë ½Å°æ°ú ) 
Åä·Ð 09-24 Room3 10:30~10:40 ÆгÎÅäÀÇ  ¼ÕÇüÀº·ùÁ¤È­ÀÌÀº¿µ(Áß¾ÓÀÇ´ëÀÌÈ­ÀÇ´ë¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09-24 Room3 10:40~10:50 Break  () 
±³À°½Ã°£ 09-24 Room3 10:50~11:15 ³ëÀο¡¼­ ½ÅüȰµ¿ÀÌ ½Å±â´É ¾ÇÈ­¿Í »ç¸Á¿¡ ¹ÌÄ¡´Â ¿µÇâ  È«À¯¾Æ(°¡Å縯ÀÇ´ë ´ëÀü¼º¸ðº´¿ø) 
±³À°½Ã°£ 09-24 Room3 11:15~11:40 °í·ÉȯÀÚ¿¡¼­ ±âÀú ½ÅÀå°æÈ­Áõ Á¤µµ¿¡ µû¸¥ ½ÅÀåÁúȯ ¿¹ÈÄÆò°¡ ¿¬±¸  ÀÌÇØ°æ(¼øõÇâÀÇ´ë ¼­¿ïº´¿ø) 
±³À°½Ã°£ 09-24 Room3 11:40~12:05 Ç÷¾× Åõ¼®À» ½ÃÀÛÇÑ ³ëÀÎ ¸¸¼ºÄáÆϺ´ ȯÀÚ¿¡¼­ ½ÉÀå ±â´ÉÀÇ ¿µÇ⠺м®  ±è´Ù¿î(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 09-24 Room3 12:05~12:30 ³ë³âÀÇ ÀÎÁö±â´É Àå¾Ö ¹× µðÁöÅÐ Ä¡·áÁ¦ÀÇ °³¹ß  ±è¿©Áø(ÇѸ²ÀÇ´ë Ãáõ¼º½Éº´¿ø) 
Åä·Ð 09-24 Room3 12:30~12:40 ÆгÎÅäÀÇ  ½Å¼ºÁØÀ̵¿Çü(µ¿±¹´ëÇб³ Àϻ꺴¿ø¹üÀÏ¿¬¼¼³»°ú) 
½Ä»ç 09-24 Room3 12:40~13:40 ½Ä»ç  () 
±³À°½Ã°£ 09-24 Room3 13:40~14:00 Management of anemia among CKD(Chronic Kidney Disease) patients not on dialysis  °íÀº½Ç(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-24 Room3 14:00~14:20 Management of anemia among dialysis patients  ±èµµÇü(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 09-24 Room3 14:20~14:45 Iron supplementation in the management of renal anemia  °­µ¿Çõ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-24 Room3 14:45~15:10 Recent updates in HIF-1a stabilizer  È²Çö¼®(°æÈñÀÇ´ë) 
Åä·Ð 09-24 Room3 15:10~15:30 ÆгÎÅäÀÇ  ±è¿µÈÆÀ±¼¼ÈñÁÖ¿µ¼öÁ¶¿øÁö(¾Æ»êº´¿ø°Ç¾çÀǴ뿬¼¼ÀÇ´ë°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-24 Room1 15:30~15:40 Break  () 
±³À°½Ã°£ 09-24 Room3 15:40~16:05 Mechanism of urine concentration: an update  ÃÖÈÆ¿µ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09-24 Room3 16:05~16:30 Function of the renal interstitium: current knowledge  Á¤Áö¿ë(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 09-24 Room3 16:30~16:55 Does intensive systolic blood pressure control have similar, greater, or less cardiovascular protective effects in Korean CKD population?  ±è¼­¸°(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 09-24 Room3 16:55~17:15 Thiazide diuretics for hypertension in CKD(Chronic Kidney Disease): recent research and future directions  ±è¾ç±Õ(°æÈñÀÇ´ë) 
Åä·Ð 09-24 Room3 17:15~17:30 ÆгÎÅäÀÇ  ±èÇü¿ì±èÇü·¡(¿¬¼¼ÀÇ´ë¼øõÇâÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÅÀåÇÐȸ KSN-IAC(Integrated Academic Conference) 2022 ÅëÇÕÇмú´ëȸ(1ÀÏÂ÷) : 2022-09-24""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022³â ÇѸ²´ëÇб³¼º½Éº´¿ø ¿Ü°ú °³¿øÀÇ ¿¬¼ö°­Á : 2022-09-24
´ÙÀ½±Û 2022³â ´ëÇÑÃéÀå´ãµµÇÐȸ Ãß°èÇмú´ëȸ : 2022-09-24
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 72 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 40 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 48 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 54 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 44 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 44 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 21 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 18 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 44 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 21 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 18 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 43 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 31 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 33 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 28 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷